An experimental COVID-19 vaccine currently in Phase I trials being run by the University of Cape Town has a unique design that might allow it to offer better protection against current and future variants of the SARS-CoV-2 virus. Elri Voigt provides an update on the trial and unpacks the science behind this vaccine candidate.
The head of the South African arm of a key COVID-19 vaccine clinical trial is “full of pride” for the teams’ part in the research which has shown the vaccine candidate to be more than 90% effective according to early findings released this week. It however remains unclear whether the vaccine will be available in South Africa once registered. Adele Baleta reports.